|Bid||8.15 x 800|
|Ask||8.28 x 1000|
|Day's Range||8.20 - 8.44|
|52 Week Range||7.13 - 11.74|
|Beta (5Y Monthly)||0.28|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
We feel now is a pretty good time to analyse Cytosorbents Corporation's ( NASDAQ:CTSO ) business as it appears the...
The U.S Army Medical Research and Development Command has awarded CytoSorbents Corporation (NASDAQ: CTSO), a Defense Health Agency (DHA) Sequential Phase II Small Business Innovation Research (SBIR) contract of .5 million over 28 months. The funding will be used to advance the development of the K+ontrol platform to treat severe hyperkalemia induced by traumatic injury and acute kidney injury in austere medicine. Price Action: CTSO shares are up 0.63% at $7.96 during the market trading session on the last check Tuesday. Progenity Inc (NASDAQ: PROG) has received funding from the Crohn's & Colitis Foundation's IBD Ventures program to further develop its oral Drug Delivery System to deliver targeted therapeutics for inflammatory bowel disease. Progenity's lead candidates include PGN-001, a high-concentration formulation of adalimumab, and PGN-600, a high concentration, solubilized formulation of tofacitinib. Price Action: PROG shares are trading 5.7% higher at $2.49 during the market trading session on the last check Tuesday. See more from BenzingaClick here for options trades from BenzingaWhy Are Nano-X Imaging (NNOX) Shares Plunging Today?Phio Pharma's PH-762 Shows Encouraging Antitumor Efficacy In Preclinical Studies© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
The FDA has signed off conditional approval for the STAR-T study to assess CytoSorbents Corporation's (NASDAQ: CTSO) blood purification device, CytoSorb, to remove Ticagrelor. The company can now initiate clinical trial agreement negotiations and institutional review board submissions. The randomized, controlled clinical trial was designed to support U.S. marketing submission for CytoSorb, to remove AstraZeneca Plc's (NASDAQ: AZN) Brilinta (ticagrelor) during the cardiothoracic surgery to reduce perioperative bleeding complications. Ticagrelor is one of the most commonly used blood thinners to reduce the risk of cardiac death, heart attacks, and strokes in patients with the acute coronary syndrome. It is also used to reduce the rate of stent thrombosis in patients who have been stented. However, when patients on ticagrelor require emergent cardiac surgery, the risk of severe bleeding and complications is very high. Last year in January, CytoSorb scored approval in the E.U. to remove ticagrelor during surgery requiring cardiopulmonary bypass. In April 2020, CytoSorb received FDA Breakthrough Designation to remove ticagrelor in a cardiopulmonary bypass circuit during emergent and urgent cardiothoracic surgery. Price Action: CTSO shares are down 2.2% at $8.8 in market trading hours on the last check Monday. See more from BenzingaClick here for options trades from BenzingaJNJ COVID-19 Vaccine Could Return This Week With Warning, Says Anthony FauciAstraZeneca's Tagrisso Scores Approval In China For Early Lung Cancer© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.